Drug Profile
AUR 108
Alternative Names: AUR-108Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Leukaemia; Lymphoma
Most Recent Events
- 19 Oct 2023 Phase-I clinical trials in Lymphoma (Late-stage disease, Second-line therapy or greater, Monotherapy) in India (PO) (NCT05984147)
- 31 Jul 2023 Aurigene plans a phase I ASHA-1 trial in Lymphoma (Second-line therapy, Late-stage disease) in India (PO) in August 2023 (NCT05984147)
- 04 Jan 2023 Phase-I clinical trials in Leukaemia in India, prior to January 2023 (Aurigene pipeline, January 2023)